Case todayBrokenOfficer change · Sep 29, 2026The case · mixed · Oct 15, 2026Own TPST if Tempest Therapeutics is not yet a commercial business; it is an R&D option whose value depends on converting a clinical-stage portfolio into compelling data and financing it without destroying per-share upside.5 conditions3 holding · 2 weakeningNext resultsFeb 12, 2027Projected from its filing dates

TPST at a glance

The past year

Chart

−95.7% $0.37, close Nov 13

From the highest close
−96.0%
Vs the 200-day average
−73.2%
Nov 12, 2025Daily close, Tempest TherapeuticsNov 13, 2026

Short interest

History

241,168 shares

Of shares outstanding
1.21%
Since the last report
−22.9%
Days to cover
1.9 days
Settled
Oct 30, 2026

Insider buying, 7 days

Filings

None filed this week

Form 4s filed
Nov 10 – Nov 16

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

TPST price history

Latest price$0.38Today−$0.00 (-0.26%)
TPST -40.96%S&P 500 -2.05%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • The portfolio only becomes a real economic asset if its cell therapy and small molecule candidates produce differentiated clinical evidence that a partner, regulator, or acquirer can underwrite.HoldingMateriality: High

    The profile describes Tempest as a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates. If this holds, the company can move from cash-burning R&D option to partnerable drug-development platform; if it breaks, the equity is mainly a declining cash balance.

    Watch: A trial readout shows insufficient efficacy, unacceptable safety, or no clinically meaningful differentiation versus the relevant standard of care.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    The profile describes Tempest as a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product.

    Open source ↗
  • Financing capacity, not current demand, is the binding operating constraint because the company must fund clinical development before any commercial cash engine exists.WeakeningMateriality: High

    Cash was $7.7 million at FY2025 year-end, down from $30.3 million at FY2024 year-end. If Tempest funds the next value-inflection point, common holders retain the clinical option; if it cannot, dilution, program delays, or restructuring dominate the outcome.

    Watch: A strategic partnership or licensing deal provides meaningful upfront funding.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Cash was $7.7 million at FY2025 year-end, down from $30.3 million at FY2024 year-end.

    Open source ↗
  • Management must keep burn aligned with the most valuable clinical decisions, because unfocused trial spending would force financing before the portfolio has been de-risked.HoldingMateriality: Medium

    FY2025 annual GAAP operating cash flow was negative $26.8 million, an improvement from negative $33.0 million in FY2024. Disciplined burn increases the chance that the next raise or partnership follows value creation rather than distress; undisciplined burn transfers value to new capital providers.

    Watch: Trial expansions, manufacturing commitments, or CRO cost inflation materially increase required spending before a data event.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2025 annual GAAP operating cash flow was negative $26.8 million, an improvement from negative $33.0 million in FY2024.

    Open source ↗
  • The stock can work only if new capital is raised on terms that preserve existing shareholders' claim on the pipeline, rather than merely keeping the company alive.WeakeningMateriality: Medium

    Stockholders' equity fell to $6.7 million at FY2025 year-end from $19.1 million at FY2024 year-end. Clinical success can still be a poor investment outcome if repeated distressed financings absorb most of the upside.

    Watch: A non-dilutive partnership validates a program and funds development.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Stockholders' equity fell to $6.7 million at FY2025 year-end from $19.1 million at FY2024 year-end.

    Open source ↗
  • The stated diversified portfolio only protects investors if more than one program remains scientifically credible and fundable; otherwise Tempest becomes a single-asset binary bet.HoldingMateriality: Medium

    The profile describes a diversified portfolio of cell therapy and small molecule product candidates. Real portfolio breadth gives management more paths to a partner or financing; hollow diversification leaves shareholders exposed to one clinical failure.

    Watch: Management discontinues or indefinitely pauses most non-lead programs due to cash limits.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    The profile describes a diversified portfolio of cell therapy and small molecule product candidates.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

The portfolio only becomes a real economic asset if its cell therapy and small molecule candidates produce differentiated clinical evidence that a partner, regulator, or acquirer can underwrite. If this holds, the company can move from cash-burning R&D option to partnerable drug-development platform; if it breaks, the equity is mainly a declining cash balance.

Financing capacity, not current demand, is the binding operating constraint because the company must fund clinical development before any commercial cash engine exists. If Tempest funds the next value-inflection point, common holders retain the clinical option; if it cannot, dilution, program delays, or restructuring dominate the outcome.

Management must keep burn aligned with the most valuable clinical decisions, because unfocused trial spending would force financing before the portfolio has been de-risked. Disciplined burn increases the chance that the next raise or partnership follows value creation rather than distress; undisciplined burn transfers value to new capital providers.

The stock can work only if new capital is raised on terms that preserve existing shareholders' claim on the pipeline, rather than merely keeping the company alive. Clinical success can still be a poor investment outcome if repeated distressed financings absorb most of the upside.

The stated diversified portfolio only protects investors if more than one program remains scientifically credible and fundable; otherwise Tempest becomes a single-asset binary bet. Real portfolio breadth gives management more paths to a partner or financing; hollow diversification leaves shareholders exposed to one clinical failure.

All standing thesis claims
Original report summary

Tempest Therapeutics is not yet a commercial business; it is an R&D option whose value depends on converting a clinical-stage portfolio into compelling data and financing it without destroying per-share upside.

Evidence assessed Oct 15, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Tempest Therapeutics

Where the evidence on Tempest Therapeutics disagrees: Mixed on the latest evidence (Oct 15, 2026). Of its 5 thesis points, 3 holding and 2 weakening.

Bull case: what the evidence supports

  • The portfolio only becomes a real economic asset if its cell therapy and small molecule candidates produce differentiated clinical evidence that a partner, regulator, or acquirer can underwrite.

    sec.gov ↗

  • Management must keep burn aligned with the most valuable clinical decisions, because unfocused trial spending would force financing before the portfolio has been de-risked.

    sec.gov ↗

  • The stated diversified portfolio only protects investors if more than one program remains scientifically credible and fundable; otherwise Tempest becomes a single-asset binary bet.

    sec.gov ↗

Bear case: what the evidence questions

  • Financing capacity, not current demand, is the binding operating constraint because the company must fund clinical development before any commercial cash engine exists.

    sec.gov ↗

  • The stock can work only if new capital is raised on terms that preserve existing shareholders' claim on the pipeline, rather than merely keeping the company alive.

    sec.gov ↗

Thesis-Break Engine

What has broken in Tempest Therapeutics’s thesis

Each break OptimistFi flagged on Tempest Therapeutics, dated — with what has historically followed the same kind of break across the market, not a forecast for Tempest Therapeutics.

peers+15%-20%-2%12 mo agonow+6 mo
Daily price, then where similar breaks led across the market: the typical -2% path vs comparable companies over six months, inside the middle-half range (+15% to -20%). A base rate, not a forecast.
  • CEO / officer changecondition set before this filing

    Across all companies, this kind of break has happened 16,849 times before. Those stocks trailed comparable companies by a median of 2% over the next six months, and 38% of them trailed it by 10 points or more.

How the Thesis-Break Engine works →Historical outcomes are measured against comparable companies after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Entered a material definitive agreement.

    Tempest Therapeutics filed an SEC 8-K on 2026-09-28: Entered a material definitive agreement. It is a dated development that tests the current thesis.

  2. Mixed
    Entered a material definitive agreement.

    Tempest Therapeutics filed an SEC 8-K on 2026-09-17: Entered a material definitive agreement. It is a dated development that tests the current thesis.

  3. Mixed
    Other material event.

    Tempest Therapeutics filed an SEC 8-K on 2026-09-16: Other material event. It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • A trial readout shows insufficient efficacy, unacceptable safety, or no clinically meaningful differentiation versus the relevant standard of care.
  • A strategic partnership or licensing deal provides meaningful upfront funding.
  • Trial expansions, manufacturing commitments, or CRO cost inflation materially increase required spending before a data event.
  • A non-dilutive partnership validates a program and funds development.
  • Management discontinues or indefinitely pauses most non-lead programs due to cash limits.

TPST news

Loading headlines…

Financial statements

TPST income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

TPST: quick answers

When does Tempest Therapeutics (TPST) report earnings next?
Tempest Therapeutics's next results are projected for February 12, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 13, 2026. Earnings calendar
What is TPST's short interest?
As of October 30, 2026, 241,168 TPST shares were sold short, 1.21% of its shares outstanding, down 22.9% from the count before. At the stock's average daily volume that is 1.9 days to cover. FINRA publishes the count twice a month. TPST short interest history
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.